HC Wainwright Has Negative Forecast for ZNTL Q1 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a report released on Thursday, March 27th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.52) for the quarter, down from their previous forecast of ($0.41). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals' Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.11) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.61) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($0.99) EPS.

Other analysts have also recently issued research reports about the company. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. Wedbush reaffirmed a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. Finally, UBS Group dropped their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $8.24.

Remove Ads

Zentalis Pharmaceuticals Stock Down 5.2 %

NASDAQ:ZNTL traded down $0.07 during trading hours on Monday, hitting $1.29. 645,349 shares of the company's stock traded hands, compared to its average volume of 1,533,359. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $16.21. The business's fifty day simple moving average is $1.97 and its two-hundred day simple moving average is $2.81. The firm has a market cap of $92.28 million, a P/E ratio of -0.52 and a beta of 1.75.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Integral Health Asset Management LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth approximately $3,182,000. Verition Fund Management LLC grew its holdings in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after acquiring an additional 951,500 shares during the last quarter. Almitas Capital LLC grew its holdings in Zentalis Pharmaceuticals by 69.3% in the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock worth $4,929,000 after acquiring an additional 665,968 shares during the last quarter. Boxer Capital Management LLC purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $1,364,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock valued at $2,605,000 after acquiring an additional 370,511 shares during the last quarter.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of the business's stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ingmar Bruns acquired 20,000 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was bought at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now owns 36,629 shares of the company's stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company's stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.